Previous 10 | Next 10 |
Merus N.V. (MRUS) is expected to report $-0.73 for Q3 2023
- 37% ORR and 14.9 months median DOR in 78 evaluable NRG1+ NSCLC patients - 42% ORR and 9.1 months median DOR in 33 evaluable NRG1+ PDAC patients - Sufficient clinical data expected in 1H24 to support potential BLA submissions UTRECHT, The Netherlands and CAMBRIDGE, Mass., O...
Zeno interim clinical data continues to show robust efficacy in NRG1+ NSCLC and PDAC: Sufficient clinical data expected in 1H24 to support potential BLA submissions Petosemtamab 2L+ HNSCC phase 3 trial design supported by INTERLINK-1 control arm Clinical data update on petosem...
2023-10-13 09:00:17 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – October 13, 2023 – USA News Group – Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer ...
Mini Oral: MCLA-129 in combination with osimertinib in treatment naïve, and after progression on osimertinib, non-small cell lung cancer Poster: MCLA-129 in previously treated head & neck squamous cell carcinoma UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 06, 2023 (GLOB...
2023-09-26 10:50:17 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 26, 2023 – USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an ...
2023-08-30 21:22:13 ET Summary Merus stock has cooled down after a strong rally, but long-term investors are sitting on a 47% gain since January. The company's pipeline includes promising clinical assets, but sentiment towards the stock is mixed and price structure has broken down...
2023-08-10 14:30:08 ET Merus ( NASDAQ: MRUS ) has priced an underwritten public offering to raise $150 million, the company said Thursday. The company will offer 6,818,182 common shares at $22 apiece. The offer price represents a 3.9% discount to Wednesday's closing p...
2023-08-09 16:19:53 ET Merus N.V. ( NASDAQ: MRUS ) plans to offer and sell its common shares through an underwritten public offering, the company said Wednesday. All of the common shares are being offered by Merus. The underwriters will have a 30-day option to pu...
2023-08-07 17:23:23 ET Merus press release ( NASDAQ: MRUS ): Q2 GAAP EPS of -$0.66 beats by $0.21 . Revenue of $10.48M (-17.4% Y/Y) misses by $0.89M . For further details see: Merus GAAP EPS of -$0.66 beats by $0.21, revenue of $10.48M misses by $0.89M
News, Short Squeeze, Breakout and More Instantly...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...
2024-07-13 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...